Journal Article

Stroma gene signature predicts responsiveness to chemotherapy in pancreatic ductal adenocarcinoma patient‐derived xenograft models

Anastasia, Alessia, Micotti, Edoardo, Belotti, Dorina, Scanziani, Eugenio, Giavazzi, Raffaella, Morosi, Lavinia, Matteo, Cristina, Fioravanti, Claudia, Minoli, Lucia, Ghilardi, Carmen, Chiorino, Giovanna, Formenti, Laura, Resovi, Andrea, Ostano, Paola

2025

Overview

Despite many efforts to understand the molecular mechanisms of pancreatic ductal adenocarcinoma (PDAC) treatment resistance, there is still no reliable method for selecting patients who could benefit from standard pharmacological treatment. Here, four PDAC patient‐derived xenografts (PDAC‐PDXs) with different responses to gemcitabine plus nab‐paclitaxel (nanoparticle albumin‐bound paclitaxel) were studied to dissect the contribution of both tumor and host microenvironment to treatment response. PDAC‐PDXs transplanted into the pancreas of immunodeficient mice retained the main genetic and histopathological characteristics of the original human tumors, including invasiveness and desmoplastic reaction. Response to chemotherapy was associated with a specific 294 stroma gene signature and was not due to the intrinsic responsiveness of tumor cells or differences in drug delivery. Human dataset analysis validated the expression of the 294 stroma gene signature in PDAC clinical samples, confirming PDAC‐PDXs as a useful tool to study the biology of tumor–host interactions and to test drug efficacy. In summary, we identified a stroma gene signature that differentiates PDAC‐PDXs that are responsive to gemcitabine plus Nab‐paclitaxel treatment from those that are not, confirming the active role of the tumor microenvironment in the drug response. Pancreatic ductal adenocarcinoma patient‐derived xenografts (PDAC‐PDXs) engrafted orthotopically in the pancreas of immunodeficient mice retain the main genetic and histopathological characteristics of the original human tumors. A 294 stroma gene signature differentiates between PDAC‐PDXs that are responsive to gemcitabine plus nab‐paclitaxel versus those that are nonresponsive, suggesting an active role of the tumor microenvironment in drug response.

• Publisher: John Wiley & Sons, Inc,John Wiley and Sons Inc,Wiley
• Subject: Adenocarcinoma / Adjuvants / Albumins - pharmacology / Animals / Cancer Therapies / Carcinoma, Pancreatic Ductal - drug therapy / Carcinoma, Pancreatic Ductal - genetics / Carcinoma, Pancreatic Ductal - pathology / Chemotherapy / Clinical trials / Datasets / Deoxycytidine - administration & dosage / Deoxycytidine - analogs & derivatives / Deoxycytidine - pharmacology / Deoxycytidine - therapeutic use / Drug delivery / Drug dosages / Drug therapy / Female / Fibroblasts / Gemcitabine / Gene expression / Gene Expression Regulation, Neoplastic - drug effects / Humans / Immune system / Immunodeficiency / Immunohistochemistry / Immunotherapy / Invasiveness / Magnetic resonance imaging / Male / Mass spectrometry / Medical prognosis / Mice / Molecular modelling / Nanoparticles / Ontology / Paclitaxel / Paclitaxel - pharmacology / Paclitaxel - therapeutic use / Pancreas transplantation / Pancreatic Cancer / Pancreatic Neoplasms - drug therapy / Pancreatic Neoplasms - genetics / Pancreatic Neoplasms - pathology / Patients / patient‐derived xenografts / Scientific imaging / Software / Stroma / stroma signature / Stromal Cells - drug effects / Stromal Cells - metabolism / Stromal Cells - pathology / Transcriptome / treatment response / Tumor cells / Tumor microenvironment / Tumor Microenvironment - drug effects / Tumor Microenvironment - genetics / Tumors / Xenograft Model Antitumor Assays / Xenografts